Real-world Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate or Severe Hemophilia A: An Analysis of the Adelphi Hemophilia Disease Specific Programme™

Oral presentation is available to registered attendees only via the ASH annual meeting virtual platform, as per congress regulations. 

Session Name: 322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations

Session Date: Saturday, December 7, 2024

Session Time: 12:00 PM - 1:30 PM

Presentation Time: 1:00 PM

Study funded by Sanofi.

Link to Published Abstract